The DOI matches its Crossref record; 499 of the 502 references it cites were found in a registry or an index.
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease
Open accessAbstract
PREAMBLE The study of NAFLD has intensified significantly, with more than 1400 publications since 2018, when the last American Association for the Study of Liver Diseases (AASLD) Guidance document was published.1 This new AASLD Guidance document reflects many advances in the field pertinent to any practitioner caring for patients with NAFLD and emphasizes advances in noninvasive risk stratification and therapeutics. A separate guideline focused on the management of patients with NAFLD in the context of diabetes has been written jointly by the American Association of Clinical Endocrinology and AASLD.2 Given the significant growth in pediatric NAFLD, it will not be covered here to allow for a more robust discussion of the diagnosis and management of pediatric NAFLD in the upcoming AASLD Pediatric NAFLD Guidance. A “Guidance” differs from a “Guideline” in that it is not bound by the Grading of Recommendations, Assessment Development and Evaluation system. Thus, actionable statements rather than formal recommendations are provided herein. The highest available level of evidence was used to develop these statements, and, where high-level evidence was not available, expert opinion was used to develop guidance statements to inform clinical practice. Key points highlight important concepts relevant to understanding the disease and its management. The most profound advances in NAFLD relevant to clinical practice are in biomarkers and therapeutics. Biomarkers and noninvasive tests (NITs) can be used clinically to either exclude advanced diseases or identify those with a high probability of cirrhosis.3,4 NIT “cut points” vary with the populations studied, underlying disease severity, and clinical setting. Those proposed in this guidance are meant to aid decision-making in the clinic and are not meant to be interpreted in isolation. Identifying patients with “at-risk” NASH (biopsy-proven NASH with stage 2 or higher fibrosis) is a more recent area of interest. Although the definitive diagnosis and staging of NASH remain linked to histology, noninvasive tools can now be used to assess the likelihood of significant fibrosis, predict risk of disease progression and decompensation, make management decisions, and, to some degree, assess response to treatment. There is an ongoing debate over the nomenclature of fatty liver disease, which had not been finalized at the time this guidance was published. At the culmination of a rigorous consensus process, it is intended that any formal change in nomenclature will advance the field without a negative impact on disease awareness, clinical trial endpoints, or the drug development/approval process. Furthermore, it should allow for the emergence of newly recognized disease subtypes to address the impact of disease heterogeneity, including the role of alcohol, on disease progression and response to therapy. Input from patients has been central to all stages of the consensus process to ensure the minimization of nomenclature-related stigma. DEFINITIONS NAFLD is an overarching term that includes all disease grades and stages and refers to a population in which ≥5% of hepatocytes display macrovesicular steatosis in the absence of a readily identified alternative cause of steatosis (eg, medications, starvation, monogenic disorders) in individuals who drink little or no alcohol (defined as < 20 g/d for women and <30 g/d for men). The spectrum of disease includes NAFL, characterized by macrovesicular hepatic steatosis that may be accompanied by mild inflammation, and NASH, which is additionally characterized by the presence of inflammation and cellular injury (ballooning), with or without fibrosis, and finally cirrhosis, which is characterized by bands of fibrous septa leading to the formation of cirrhotic nodules, in which the earlier features of NASH may no longer be fully appreciated on a liver biopsy. UPDATE ON EPIDEMIOLOGY AND NATURAL HISTORY The prevalence of NAFLD and NASH is rising worldwide in parallel with increases in the prevalence of obesity and metabolic comorbid disease (insulin resistance, dyslipidemia, central obesity, and hypertension).5,6 The prevalence of NAFLD in adults is estimated to be 25%–30% in the general population7–9 and varies with the clinical setting, race/ethnicity, and geographic region studied but often remains undiagnosed.10–14 The associated economic burden attributable to NASH is substantial.15–17 The prevalence of NASH in the general population is challenging to determine with certainty; however, NASH was identified in 14% of asymptomatic patients undergoing colon cancer screening.14 This study also highlights that since the publication of a prior prospective prevalence study,18 the prevalence of clinically significant fibrosis (stage 2 or higher fibrosis) has increased >2-fold. This is supported by the projected rise in NAFLD prevalence by 2030, when patients with advanced hepatic fibrosis, defined as bridging fibrosis (F3) or compensated will the proj
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Based on this, it seems reasonable to conclude that should patients continue to complete guideline-based amounts of aerobic exercise over a longer duration, fibrosis improvement may follow [35, 36].”
From Aerobic Exercise Training Leads to MASH Resolution as Defined by the MASH Resolution Index (2026) · cites this paper as [35]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Moreover, interventions in diet and physical activity are considered to be the cornerstone of management in the whole MASLD spectrum [7, 10].”
From Effects of Mediterranean diet, exercise, and their combination on body composition and liver outcomes in metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis of randomized controlled trials (2025) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although there is no consensus on the optimal diet for treating MASLD, the EASL-EASD-EASO guidelines recently recommended the MD as the preferred option [7, 10].”
From Effects of Mediterranean diet, exercise, and their combination on body composition and liver outcomes in metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis of randomized controlled trials (2025) · cites this paper as [7]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Current guidelines recommend weight loss through dietary modifications, increased physical activity, or both combined in MASLD patients [7, 11, 12].”
The cited source says what the claim attributes to it.
In the citing paper
“Various scienti fi c societies have recommended clinical care pathways with an emphasis on the use of non-invasive tests (NITs) and the liaison between primary care/non-hepatology and hepatology settings.”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [126]
In the citing paper
“GLP-1RA-based drugs have been proven beneficial to some extent in dedicated trials and should be considered in patients with obesity and/or T2D and metabolic dysfunction-associated steatohepatitis (MASH)90.”
From Incretin-based therapies for the treatment of obesity-related diseases (2024) · cites this paper as [90]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Self-citationYounossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
Self-citationSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Sterling, R. K., Lissen, E., Clumeck, N., Sola, R., Correa, M. C., Montaner, J., S. Sulkowski, M., Torriani, F. J., Dieterich, D. T., Thomas, D. L., et al. (2006) · Hepatology · doi:10.1002/hep.21178 · Cited by 5,021
Effects of Bariatric Surgery on Mortality in Swedish Obese Subjects
Sjöström, L., Narbro, K., Sjöström, C. D., Karason, K., Larsson, B., Wedel, H., Lystig, T., Sullivan, M., Bouchard, C., Carlsson, B., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066254 · Cited by 4,668
Marrero, J. A., Kulik, L., Sirlin, C. B., Zhu, A. X., Finn, R. S., Abecassis, M. M., Roberts, L. R., & Heimbach, J. K. (2018) · Hepatology · doi:10.1002/hep.29913 · Cited by 4,597
Mechanisms of NAFLD development and therapeutic strategies
Friedman, S. L., Neuschwander-Tetri, B. A., Rinella, M., & Sanyal, A. J. (2018) · Nature Medicine · doi:10.1038/s41591-018-0104-9 · Cited by 4,354
Self-citation
Cited by
Sorted by citations
Items 801–900 of 1,002
Recent advances in noninvasive assessment of liver steatosis
Ferraioli, G., & Barr, R. G. (2024) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.16703 · Cited by 8
Chen, S., Zeng, Q., Cai, X., Xue, J., Yin, G., Song, P., Tang, L., Klein, C., Tacke, F., Guillot, A., et al. (2024) · International Journal of Biological Sciences · doi:10.7150/ijbs.98362 · Cited by 8
Shengir, M., Lebouché, B., Elgretli, W., Saeed, S., Ramanakumar, A. V., Giannakis, A., de Pokomandy, A., Cox, J., Costiniuk, C. T., Routy, J., et al. (2023) · HIV Medicine · doi:10.1111/hiv.13531 · Cited by 7
“Exclusion criteria were any among: (1) HCV antibody positive; (2) hepatitis B surface antigen positive; (3) significant alcohol intake [16]; (4) pregnancy or breastfeeding; (5) AIDS-defining opportunistic disease in the 24 weeks before recruitment; (6) history of decompensated liver disease,…”
BackgroundChu, J. N., Goldman, M. L., Brandman, D., Sohn, J. H., Islam, K. B., Ross, L. A., & Fox, R. K. (2023) · The American Journal of Medicine · doi:10.1016/j.amjmed.2023.10.002 · Cited by 7
Kumar, S. R., Mohanty, A., Mantry, P., Schwartz, R. E., Haff, M. G., Therapondos, G., Noureddin, M., Dieterich, D. T., Girgrah, N., Cohn, K., et al. (2024) · BMC Family Practice · doi:10.1186/s12875-024-02517-y · Cited by 7
“…for the Study of Liver Disease (AASLD), the American Diabetes Association (ADA), the American Gastroenterological Association (AGA), and the American Association of Clinical Endocrinology (AACE), have been published within the last five years with a focus on screening high-risk populations [7–10].”
BackgroundEndoscopic sleeve gastroplasty for metabolic dysfunction-associated steatotic liver disease
Matteo, M. V., Gualtieri, L., Bove, V., Palumbo, G., Pontecorvi, V., Siena, M. D., Barbaro, F., Spada, C., & Boškoski, I. (2024) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2024.2387231 · Cited by 7
Rigor, J., MARTINS, M. E., Passos, B., Oliveira, R., & Martins‐Mendes, D. (2024) · Minerva Medica · doi:10.23736/s0026-4806.24.09290-5 · Cited by 7
Ogawa, Y., Tomeno, W., Imamura, Y., Baba, M., Ueno, T., Kobayashi, T., Iwaki, M., Nogami, A., Kessoku, T., Honda, Y., et al. (2024) · Hepatology Research · doi:10.1111/hepr.14117 · Cited by 7
“11 The FIB - 4 relies on patient age, AST, ALT, and platelet count, which are routinely measured.”
Ebrahimi, F., Ebrahimi, R., Hagström, H., Sundström, J., Sun, J., Bergman, D., Forss, A., & Ludvigsson, J. F. (2024) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.124.010912 · Cited by 7
“22 However, to date, the clinical relevance of shared genetic and environmental risks of cardiovascular disease in family members of people with MASLD is unclear.”
Soliman, A. R., Saleem, H. M. E., Meligi, A. A. H. E., Naguib, M., Mohamed, R. S., Abdelaziz, G. R., Rakha, M., Abdelghaffar, S., Hamed, A. E., Hammad, H., et al. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-024-01564-w · Cited by 7
“Bariatric surgery can resolve NASH, improve hepatic fibrosis (with grade 2 or 3 fibrosis being resolved or improved in 60% of patients [131], induce sustained weight loss of up to 30%, cure diabetes, and decrease all-cause morbidity and mortality, with benefits observed five years after [132].”
Bera, C., Hamdan‐Pérez, N., Kosick, H. M.-K., Shengir, M., Sebastiani, G., & Patel, K. (2025) · Canadian Liver Journal · doi:10.3138/canlivj-2024-0063 · Cited by 7
Impact of Weight Loss on Metabolic Dysfunction Associated Steatohepatitis and Hepatic Fibrosis
Takawy, M., & Abdelmalek, M. F. (2025) · Current Diabetes Reports · doi:10.1007/s11892-025-01579-1 · Cited by 11
“As with the multidisciplinary approaches used to manage obesity, optimal care of patients with MASLD/ MASH requires a multidisciplinary approach involving primary care providers, hepatologists, endocrinologists, nutri-tionists, and bariatric or endobariatric surgical specialists [182].”
Self-citationKim, J. H., Lee, Y., Nam, C. M., Kwon, Y., & Lee, J. (2025) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2025.103965 · Cited by 8
Schonfeld, E. A., Kierans, A. S., Fox, R. K., & Brandman, D. (2025) · Journal of the American College of Radiology · doi:10.1016/j.jacr.2024.12.014 · Cited by 7
Innovative nanomedicine approaches for the management of nonalcoholic fatty liver disease
Li, L., Gao, W., Yao, F., Li, J., Sang, W., & Zhang, R. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113680 · Cited by 8
Thallapureddy, K., Twitchell, D., Ott, K., Pedicone, L. D., Owo, C., Kumar, N., Gelfond, J., Shankar, N., Goros, M. W., Kwok, D., et al. (2025) · Medicine · doi:10.1097/md.0000000000042016 · Cited by 7
The Roles of T Cells in the Development of Metabolic Dysfunction‐Associated Steatohepatitis
Ge, Z., Wu, Q., Lv, C., & He, Q. (2025) · Immunology · doi:10.1111/imm.13943 · Cited by 7
Pugliese, N., Arcari, I., Cerini, F., Lombardi, R., Turati, F., Pennisi, G., Soleri, M., Rocchetto, S., Deo, D. D., Sagasta, M., et al. (2025) · United European Gastroenterology Journal · doi:10.1002/ueg2.70055 · Cited by 7
Phipps, M. M., Hage, T., Truong, E., Yang, J. D., Nicolosi, L., Dennis, A., Shumbayawonda, E., Pandya, P., & Wattacheril, J. J. (2025) · Digestive and Liver Disease · doi:10.1016/j.dld.2025.05.023 · Cited by 7
Li, J., Chen, J., Zeng, X., Lyu, G., Shu, L., & He, S. (2025) · PeerJ · doi:10.7717/peerj.19645 · Cited by 7
Zhang, H., Lin, F., Miao, M., Yu, C., & Guo, W. Y. (2025) · Nutrition & Metabolism · doi:10.1186/s12986-025-00951-y · Cited by 7
MASLD: insights on the role of folate in hepatic lipid metabolism
Yang, M., Xiao, X., Mei, J., Pu-Bu-Ci-Ren, & Gong, Q. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1583674 · Cited by 7
Kale, A. B., Faraşat, M., Pekindil, G., Ayhan, S., Tarhan, S., & Buran, T. (2025) · Journal of Ultrasound in Medicine · doi:10.1002/jum.70005 · Cited by 7
Cardiovascular implications of MASLD: overview of the evidence
Ismail, B., Nabilou, P., Gluud, L. L., & Møller, S. (2025) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365521.2025.2536585 · Cited by 7
“the prevalence of metabolic dysfunction-associated steatotic liver disease (MASlD) is increasing globally, affecting up to 38% of the population worldwide [1– 3].”
Lee, B. K., Ghumman, U., Pedicone, L. D., Gómez-Aldana, A., & Lawitz, E. (2025) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2025.0337 · Cited by 9
Abaalkhail, F. A., Sanai, F. M., Alswat, K., Alzanbagi, A., Al-Jedai, A. H., Alshehri, A., Alfadda, A. A., Alghamdi, H., Almadi, M. A., AlEissa, M., et al. (2025) · Saudi Journal of Gastroenterology · doi:10.4103/sjg.sjg_199_25 · Cited by 8
Wang, H., Liu, S., Chen, Y., Fang, W., Cheng, Y., Zhang, Z., Hu, B., Hu, B., & Liu, H. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.157404 · Cited by 8
Austrian multisociety consensus on metabolic dysfunction-associated steatotic liver disease
Mandorfer, M., Semmler, G., Aigner, E. S., Bräuer, A., Brix, J. M., Clodi, M., Datz, C., Effenberger, M., Felsenreich, D. M., Ludvik, B. H., et al. (2025) · Wiener klinische Wochenschrift · doi:10.1007/s00508-025-02617-4 · Cited by 7
“The following groups are at considerable risk for advanced fibrosis: type 2 diabetes mellitus, (abdominal) obesity, males> 50 years and postmenopausal women [6, 7, 16].”
InfluentialWindell, D., Magness, A. J., Beyer, C., Thomaides-Brears, H. B., Larkin, S. J., Hobson, K., Aljabar, P., Fleming, K., Fryer, E., Kendall, T. J., et al. (2025) · Journal of Clinical Pathology · doi:10.1136/jcp-2025-210311 · Cited by 8
Rabbat, J., Yang, B., Lee, H. W., Lin, H., Tsochatzis, E. A., Petta, S., Bugianesi, E., Yoneda, M., Zheng, M., Hagström, H., et al. (2025) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2025.0888 · Cited by 8
Artificial Light at Night, Sleep Disruption, and Liver Health: Implications for MASLD Pathogenesis
Nieva-Ramírez, D. G., Uribe, M., & Nuño‐Lámbarri, N. (2025) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph22111729 · Cited by 10
“Chronic exposure to ALAN, particularly during the night, has been shown to exacerbate insulin resistance, systemic inflammation, and hepatic dysfunction, especially when combined with high-fat diets [7–9].”
Liu, R., Liu, R., Liu, M., Tian, Y., Liu, J., Wang, Y., Sui, Q., Zhang, J., Xu, H., & Qi, Z. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1659998 · Cited by 7
Erfanifar, A., Nikpour, S., Davoudi, Z., Jolfaei, P., Toreyhi, H., & Nasab, S. N. M. (2025) · BMC Endocrine Disorders · doi:10.1186/s12902-025-02098-6 · Cited by 10
“In line with AASLD guidance, we therefore treated FIB-4/NFS as supportive monitoring tools and based causal inferences primarily on objective endpoints (MRI-derived liver fat and adjusted changes in ALT/AST/GGT) [27].”
Borges, R. D. S., de Abreu, E. S., Berton, G. G., de Paula, L. H., Conegundes, A. F., Martins, J. M. B., Martins, M. A. B., Dahbour, A., Fernandes, M. V., & Abdelmalek, M. F. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101708 · Cited by 10
Self-citationNutrition in MASLD: a patient focused, evidence-based clinician’s guide
Pekarska, K., Brennan, P. N., Wajcman, D. I., Towey, J., Cox, L., Weatherby, K., McPherson, S., Stine, J., Willemse, J., Li, W., et al. (2025) · Frontline Gastroenterology · doi:10.1136/flgastro-2025-103183 · Cited by 7
“27 28”
Tincopa, M. A., Speliotes, E. K., Valenti, L. V. C., & Loomba, R. S. (2026) · Annual Review of Medicine · doi:10.1146/annurev-med-050324-124753 · Cited by 7
Self-citationTamaki, N., Kimura, T., Wakabayashi, S., Yamazaki, T., Iwadare, T., Tanaka, N., & Kurosaki, M. (2026) · Japanese Journal of Radiology · doi:10.1007/s11604-025-01930-2 · Cited by 10
Chen, Y., Qiao, X., Zou, X., Xu, K., Gu, Z., Chen, G., & Dai, J. (2026) · Frontiers in Physiology · doi:10.3389/fphys.2025.1679094 · Cited by 7
Atabaki, N. N., Coral, D., Pomares‐Millan, H., Smith, K., Behjat, H., Koivula, R. W., Tura, A., Miller, H., Pinnick, K. E., Agudelo, L. Z., et al. (2026) · Metabolism · doi:10.1016/j.metabol.2026.156552 · Cited by 7
Sharpton, S. R., Díaz, L. A., Pepin, K. M., Amangurbanova, M., Madamba, E. V., Bettencourt, R., Singh, S., Valasek, M. A., Dalupang, M., Tesfai, K., et al. (2026) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70696 · Cited by 7
Self-citationLi, F., Li, H., Juramt, D., Kou, K., Tacke, F., & Chen, L. (2026) · BMJ Open Gastroenterology · doi:10.1136/bmjgast-2026-002343 · Cited by 8
Ichikawa, K., Hansen, S. L., Manubolu, V. S., Pourafkari, L., Fazlalizadeh, H., Aldana-Bitar, J., VanWagner, L. B., Krishnan, S., & Budoff, M. J. (2023) · American Heart Journal · doi:10.1016/j.ahj.2023.07.008 · Cited by 7
Kalopitas, G., Mouskeftara, T., Liapikos, T., Arvanitakis, K., Ioannidis, A., Malandris, K., Theocharidou, E., Chourdakis, M., Sinakos, E., Gika, H., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241612717 · Cited by 7
“Patients with NAFLD, who had indications according to current clinical practice guidelines [1,2], underwent ultrasound-guided percutaneous liver biopsy [1,2].”
BackgroundMethodWu, Y., Xia, C., Chen, J., Qin, Q., Ye, Z., & Song, B. (2023) · Abdominal Radiology · doi:10.1007/s00261-023-04064-z · Cited by 7
Arvaniti, P. (2023) · Annals of Gastroenterology · doi:10.20524/aog.2023.0841 · Cited by 7
Ichikawa, T., Oba, H., Owada, M., Watanabe, K., Yoshimura, T., Fuchigami, A., & Nakamura, A. (2023) · JGH Open · doi:10.1002/jgh3.13012 · Cited by 9
“2,3 Although the guidelines for the management of NAFLD/ NASH recommend lifestyle interventions with diet modi fi cation and exercise for weight management, 4 – 6 the response to such interventions remains limited for many patients.”
BackgroundFantasia, K. L., Austad, K., Mohanty, A., Long, M. T., Walkey, A. J., & Drainoni, M. (2024) · Endocrine Practice · doi:10.1016/j.eprac.2023.12.016 · Cited by 7
Peppas, S., Doumas, S., Suvarnakar, A. M., Chou, J., Arafat, A., Ahmad, A. I., & Lewis, J. H. (2024) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000002754 · Cited by 9
“Furthermore, in diabetic patients with MASH, medical therapies that have been shown to improve fibrosis and liver histology include pioglitazone and glucagon-like peptide-1 (GLP-1) agonists [27].”
BackgroundResultGosnell, J., Golovko, G., Arroyave, E., Moghe, A., Kueht, M., Saldarriaga, Ó. A., McKinney, K. H., Stevenson, H. L., & Ferguson, M. R. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v15.i5.886 · Cited by 8
Proton pump inhibitor use is associated with increased liver steatosis
Yu, H., Li, M., Yang, B., Sun, H., Jiang, H., Liang, Z., Smayi, A., Wu, B., & Yang, Y. (2024) · Biomedical Reports · doi:10.3892/br.2024.1804 · Cited by 7
“…for the Study of Liver Diseases Practice Guidance on the Clinical Assessment and Management of Non‑alcoholic Fatty Liver Disease (NAFLD) (17), steatotic liver disease is diagnosed histologically or through imaging techniques such as ultrasound, FibroScan (CAP), Computed Tomography, and…”
BackgroundCardio-reno-Metabolic health: discussing the recommendations of the American Heart Association
Izmaylova, M. Y., Demidova, T. Y., & Владимировна, В. В. (2024) · FOCUS Endocrinology · doi:10.62751/2713-0177-2024-5-2-16 · Cited by 7
Disease modifiers and novel markers in hepatitis B virus-related hepatocellular carcinoma
Mak, L. (2024) · Journal of Liver Cancer · doi:10.17998/jlc.2024.08.03 · Cited by 7
“88 While LSM and ELF are widely available in many clinical settings, and endorsed in clinical practice guidelines for other liver diseases, 89,90 M2BPGi remains to be a research tool.”
MethodFishman, J., Kim, Y., Charlton, M., Smith, Z. J., O’Connell, T., & Bercaw, E. (2024) · Advances in Therapy · doi:10.1007/s12325-024-02989-5 · Cited by 7
“Our model incorporates a variety of NIT techniques, aligning with NASH diagnostic guidelines that recommend different NIT cut-offs and procedures [3, 8–10, 12, 22, 27, 28].”
MethodIncreased risk of vascular complications in patients with type 2 diabetes and fatty liver disease
Sun, W., Liu, D., Yang, T., Zhou, Z., Li, D., Zhao, Z., Zhang, X., Wang, L., & Li, L. (2024) · BMC Endocrine Disorders · doi:10.1186/s12902-024-01766-3 · Cited by 7
Clinical Insights on Resmetirom
Kaya, E., Yilmaz, Y., & Alkhouri, N. (2025) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000002150 · Cited by 7
“26 Indeed, tirzepatide has shown promising results in MASH treatment, demonstrating the ability to improve MASH without worsening fi brosis, as well as to improve fi brosis by at least 1 stage without exacerbating MASH.”
Wegermann, K., Diehl, A. M., & Moylan, C. A. (2023) · Hepatoma Research · doi:10.20517/2394-5079.2022.92 · Cited by 8
Fatty liver and celiac disease: Why worry?
Narciso-Schiavon, J. L., & Schiavon, L. D. L. (2023) · World Journal of Hepatology · doi:10.4254/wjh.v15.i5.666 · Cited by 7
Li, W., Sheridan, D. A., McPherson, S., Alazawi, W., Abeysekera, K. W. M., Marjot, T., Brennan, P., Mahgoub, S., Cacciottolo, T. M., Hydes, T., et al. (2023) · JHEP Reports · doi:10.1016/j.jhepr.2023.100897 · Cited by 7
Apelin and the gut microbiome: Potential interaction in human MASLD
Effenberger, M., Grander, C., Hausmann, B., Enrich, B., Pjevac, P., Zoller, H., & Tilg, H. (2023) · Digestive and Liver Disease · doi:10.1016/j.dld.2023.11.023 · Cited by 8
Gil-Rojas, S., Suárez, M., Martínez-Blanco, P., Torres, A., Martínez-García, N., Blasco, P., Torralba, M., & Mateo, J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25041996 · Cited by 8
“Among these, alcohol consumption was recorded, with harmful consumption defined as >30 g/day in males and >20 g/day in females [55]; smoking status was categorized as being a smoker or former smoker compared to those who had never smoked.”
BackgroundYin, H., Xiong, B., Yu, J., Fan, Y., Zhou, B., Sun, Y.-K., Wang, L., Xu, H., & Zhu, Y. (2024) · European Journal of Radiology · doi:10.1016/j.ejrad.2024.111427 · Cited by 7
Chan, W. L., Kumar, C. V. C., & Chan, W. (2023) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn-23-346 · Cited by 7
“Noureddin namely fibrosis-4 score as the initial test, followed by a second test (e.g., LSM, using the 8 and 12 kPa cut-offs), for the identification of patients with advanced fibrosis (11,12).”
Using NIS2+™ to identify at-risk MASH in clinical trials
Lai, J. C., & Wong, V. W. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.11.009 · Cited by 7
Huang, C., Zhou, X., Pan, C. Q., & Zheng, M. (2024) · World Journal of Gastroenterology · doi:10.3748/wjg.v30.i22.2839 · Cited by 7
Ravndal, L., Lindvig, K. P., Jensen, E. L., Sunde, A. L., Nassehi, D., Thiele, M. S., Krag, A. A., & Kjosavik, S. R. (2023) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2023.2255522 · Cited by 6
“Our findings are in line with the clinical guidelines from the European Association for the Study of the Liver [41] and the American Association for the study of Liver Diseases [42].”
ResultFIB-4 as a Time-varying Covariate and Its Association With Severe Liver Disease in Primary Care
Schreiner, A. D., Zhang, J., Moran, W. P., Koch, D., Marsden, J. E., Livingston, S., Bays, C., Mauldin, P. D., & Gebregziabher, M. (2023) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000001935 · Cited by 7
“28,34 Known CLD and advanced fi brosis should also prompt referral to a hep-atologist.”
El‐Kassas, M., Othman, H. A., Elbadry, M., Alswat, K., & Yilmaz, Y. N. (2024) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2024.102415 · Cited by 6
Malandris, K., Arampidis, D., Mainou, M., Papadopoulos, N., Karagiannis, T., Nayfeh, T., Liakos, A., Sinakos, E., Τσάπας, Α., & Bekiari, E. (2024) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.16770 · Cited by 7
Fang, X., Yin, Y., Zhao, H., Wang, C., Li, H., Shang, Y., Li, J., Gao, Y., Méndez‐Sánchez, N., & Qi, X. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1481051 · Cited by 6
Musso, G., Alberto, M., Mariano, F., Cassader, M., Michieli, F. D., Riva, A., Petrangolini, G., Togni, S., Pinach, S., & Gambino, R. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2424907 · Cited by 6
“…through amelioration of intestinal permeability and metabolic endotoxemia, and direct, by inhibition of NF-kB activation by LPS and NEFAs in MNCs. 7,26,27 Giovanna Petrangolini : gave substantial contributions to the study design and data acquisition, revised the work critically for important…”
Sex Differences in Body Composition and MASLD in Children With Overweight and Obesity
Uretzky, A., Cohen‐Sela, E., Yackobovitch‐Gavan, M., Simon, A. B., Midlij, E., Zaitoon, H., Borger, O., Interator, H., Amir, A. Z., Moran‐Lev, H., et al. (2025) · Acta Paediatrica · doi:10.1111/apa.70026 · Cited by 6
“Numerous non-invasive tests are employed to evaluate liver health in clinical settings [8].”
PNPLA3 gene variation modulates diet-induced improvement in liver lipid content in type 2 diabetes
Pafili, K., Zaharia, O., Straßburger, K., Knebel, B., Herder, C., Huttasch, M., Karusheva, Y., Kabisch, S., Strom, A., Nowotny, B., et al. (2025) · Clinical Nutrition · doi:10.1016/j.clnu.2025.02.032 · Cited by 8
Li, Y., Ma, X., Jia, J., & Cao, L.-Y. (2025) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2025.102573 · Cited by 6
Automated liver and spleen segmentation for MR elastography maps using U-Nets
Jaitner, N., Ludwig, J., Meyer, T., Böhm, O., Anders, M. S., Huang, B., Jordan, J. E. L., Schaeffter, T., Sack, I., & Reiter, R. (2025) · Scientific Reports · doi:10.1038/s41598-025-95157-w · Cited by 6
Fu, J., Liu, C., Yang, L., Zhang, B., Zhou, R., Deng, C., Zhang, H., Kong, J., Li, J., & Shi, J. (2025) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000002964 · Cited by 9
“Therefore, lifestyle interventions are still the primary treatment for MASLD [3,11].”
Wu, D., Liu, J., Guo, Z., Wang, L., Yao, Z., Wu, Q., Lu, Y., & Lv, W. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.114708 · Cited by 6
Deb, R., Goswami, S., Sengupta, N., Baidya, A., Khare, V. R., Datta, J., Das, M., & Ray, D. (2025) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_457_24 · Cited by 6
“[1,3,16] This study’s strength lies in its large, Indian T2D cohort, making it one of the first to propose an adjusted FIB-4 threshold specific to this population.”
LY3522348, A New Ketohexokinase Inhibitor: A First-in-Human Study in Healthy Adults
Fukuda, T., Thompson, B. R., Brouwers, B., Qian, H.-R., Wang, W. J., Morse, B. L., LaBell, E. S., Durham, T. B., Кониг, М., Haupt, A., et al. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01752-5 · Cited by 6
“This, in turn, contributes to the development of type 2 diabetes, obesity, and other metabolic diseases [5–7].”
Hakim, A., Lin, K.-H., Schwantes-An, T.-H. L., Abreu, M., Tan, J., Guo, X., Yates, K. P., Lotta, L. A., Verweij, N., Loomba, R. S., et al. (2025) · Hepatology Communications · doi:10.1097/hc9.0000000000000728 · Cited by 6
“[2] The gold standard for the definite diagnosis of MASH and/or evaluation of its severity is a liver biopsy.”
Self-citationMa, H., Zhang, W., Zhao, Z., Jin, S., Li, L., Zong, R., Li, W., Zhang, Z., Cui, S., Pan, Y., et al. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1604991 · Cited by 6
Complexity of metabolic dysfunction–associated steatotic liver disease: State of the art review
Yeh, H., Lin, S. J., Shen, H., Li, T., Tsai, H., Yang, Y., Lin, H.-C., & Hou, M. (2025) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000001254 · Cited by 6
“63,64 Similarly, the AGA recommends 150 to 300 minutes of moderate-intensity exercise or 75 to 150 minutes of vigorous-intensity exercise weekly for patients with MASLD.”
Pebriana, R. B., Chen, T., Derks, R. J. E., Blomberg, N., Grefhorst, A., Mohammed, Y., Nieuwdorp, M., Verheij, J., Doukas, M., Rensen, P. C. N., et al. (2025) · Journal of Lipid Research · doi:10.1016/j.jlr.2025.100845 · Cited by 6
Chun, H. S., Lee, M., Lee, H. A., Park, E. S., Choi, J. Y., Baek, H. S., Kim, T. H., Lin, H., Yip, T. C., Lee, H. W., et al. (2025) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2025.06.025 · Cited by 9
NMR‐Based Metabolomics Reveals Metabolic Pathway Disruptions and Potential Biomarkers for Fibrosis
Pandey, S., Marwari, D., Mishra, J., Goel, A., Mishra, A. K., & Sinha, N. (2025) · Magnetic Resonance in Chemistry · doi:10.1002/mrc.70017 · Cited by 6
Sukocheva, O. A., Ow, T., Harding, D., Mire, M. L., & Tse, E. (2025) · World Journal of Hepatology · doi:10.4254/wjh.v17.i7.106675 · Cited by 6
Sedhom, S. S., Wakeel, L. M. E., Barakat, E., Shousha, H. I., Shamkh, M. A., Salama, S. H., Zaky, D. Z., & Kholy, A. A. E. (2025) · Therapeutic Advances in Chronic Disease · doi:10.1177/20406223251358659 · Cited by 6
“6,7 Along with insulin resistance, oxidative stress (OS) plays a crucial role in the transition from simple steatosis to MASH.”
Mantovani, A., Lombardi, R., Dalbeni, A., Morandin, R., Lando, M. G., Fiorio, V., Rolli, N., Forti, M. D., Messetti, D., Zoncapè, M., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70245 · Cited by 6
“1,7,8,16 Specifically, initial risk stratification with the FIB-4 index, followed by confirmatory evaluation with VCTE among patients with T2DM who have FIB-4 Note : Sample size, n = 1203.”
Diagnosis of Portal Hypertension
Møller, S., Danielsen, K. V., Hobolth, L., Mortensen, C., & Kimer, N. (2025) · Diagnostics · doi:10.3390/diagnostics15212774 · Cited by 6
Caturano, A., Nilo, D., Lorenzo, G. D., Rocco, M. P., Tagliaferri, G., Piacevole, A., Donnarumma, M., Iadicicco, I., Moretto, S. M., Acierno, C., et al. (2025) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm43143 · Cited by 9
“MASLD is the most common chronic liver disease worldwide, and insulin resistance (IR) is widely recognized as a central driver of its pathogenesis [22].”
Nichols, L. B., Oakes, S. G. J., Behling, C. A., Adams, K. H., Fishbein, M. H., Hertel, P. M., Jarasvaraparn, C., Molleston, J. P., Mouzaki, M., Sirlin, C. B., et al. (2025) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1002/jpn3.70284 · Cited by 6
“13 20 Given these gaps, we conducted this study to evaluate the diagnostic performance of CAP and LSM in children with MASLD, using liver histology as the reference standard.”
Simonetto, D. A., Rushlow, D. R., Liu, K., Calleri, A., Kassmeyer, B. A., Lennon, R. J., Rattan, P., Bernard, M., Singh, G., Deyo-Svendsen, M. E., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-04058-y · Cited by 9
“For VCTE, the cutoffs were 10 kPa for advanced CLD and 8 kPa for any fibrosis 44,45 .”
An AI-powered tongue image model for home-based monitoring of liver fibrosis
Lu, X.-Z., Liu, S., Lin, X.-X., Zeng, Y., Chen, J.-H., Ke, W.-P., Deng, J.-F., Cheng, M.-Q., Li, W., Chen, L.-D., et al. (2025) · npj Digital Medicine · doi:10.1038/s41746-025-02246-1 · Cited by 6
“Therefore, dynamic monitoring and early detection of liver fi brosis are crucial for controlling disease progression and reducing the overall disease burden 3 effectively.”
Panuganti, V. K., Alluri, C. V., Mohammad, J., Dundigalla, M. R., Madala, P. K., KSSVV, S., & shaik, A. H. (2025) · World Journal of Hepatology · doi:10.4254/wjh.v17.i12.113658 · Cited by 6
Pasqua, L. G. D., Lotti, S., Trucchi, M., Palladini, G., Croce, A. C., Protopapa, F., Feletti, F., Kauschke, S. G., Sun, P., Vairetti, M., et al. (2026) · Antioxidants · doi:10.3390/antiox15010082 · Cited by 6
“The global rise of MASLD reflects the increasing incidence of metabolic syndrome that includes obesity, type 2 diabetes, dyslipidemia, and hypertension [3,4], with its prevalence reaching 60–75% in patients affected by these conditions [5,6].”
New Treatment Options for MASLD Patients with Type 2 Diabetes
Mega, A., Turri, C., Marzi, L., Dauriz, M., Sacco, R., Floreani, A., & Stasi, C. (2026) · Life · doi:10.3390/life16020254 · Cited by 8
Nabi, O., Spaak, J., Bergström, G. M. L., Engström, G., Östgren, C. J., Malinovschi, A., Kullberg, J., Blomberg, A., Jernberg, T., Andersson, D. P., et al. (2026) · Journal of Internal Medicine · doi:10.1111/joim.70071 · Cited by 7
Evaluation of Abnormal Liver Biochemical Test Results
Kwo, P. Y., Masuoka, H. C., Schaefer, E. A. K., & Friedman, L. S. (2026) · Gastroenterology · doi:10.1053/j.gastro.2025.12.041 · Cited by 7
Bril, F. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70553 · Cited by 6
Stefan, N., Hartleb, M., Fan, J., Demir, M., Schattenberg, J. M., Gietka, J., Bułdak, Ł., Popovic, B., Varona, R., & Fer, B. B. D. (2026) · Liver International · doi:10.1111/liv.70601 · Cited by 6
CT-based Opportunistic Screening for Adding Clinical Value: How I Do It
Pickhardt, P. J., Lee, M. V., Warner, J., Summers, R. M., & Garrett, J. W. (2026) · Radiology · doi:10.1148/radiol.252106 · Cited by 6
Metadata
- Authors
- Rinella, M. E., Neuschwander-Tetri, B. A., Siddiqui, M. S., Abdelmalek, M. F., Caldwell, S., Barb, D., Kleiner, D. E., & Loomba, R.
- Affiliations
- University of Chicago (US)
- Saint Louis University School of Medicine, Saint Louis, Missouri, USA
- Virginia Commonwealth University (US)
- Mayo Clinic (US)
- University of Virginia (US)
- University of Florida Health (US)
- National Institutes of Health (US)
- University of California San Diego (US)
- Corresponding author
- Rinella, Mary E.
- ORCID
- Venue
- Hepatology
- Published
- 2023-03-17
- Volume
- 77
- Issue
- 5
- Pages
- 1797-1835
- ISSN
- 0270-9139 (ISSN-L)
- PMC
- PMC10735173
- OpenAlex
- W4318923555
- Cited by
- 2,667
- References
- 502
- Citations by year
- 2026: 849 · 2025: 845 · 2024: 691 · 2023: 281
- FWCI
- 532.31
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Hepatology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- Bristol-Myers Squibb
- American Association for the Study of Liver Diseases
- NGM Biopharmaceuticals
- Novo Nordisk
- National Institutes of Health
- Allergan
- National Cancer Institute (ZICBC010685)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
- Keywords
- non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, non-invasive risk stratification, non-invasive tests, fibrosis staging, liver cirrhosis
- MeSH terms
- Humans, Liver, Liver Cirrhosis, Disease Progression, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
